Related Experiment Videos
Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer
P Stricker1, K Pryor, T Nicholson
1Department of Urology, St. Vincent's Hospital, University of New South Wales, Sydney, Australia.
Insights
This study combined low-dose Bacillus Calmette-Guérin (BCG) with interferon alpha-2b (IFN alpha 2b) for bladder cancer treatment. The combination therapy was safe, well-tolerated, and showed promising early results with no tumor progression in most patients.
Area of Science:
- Oncology
- Immunotherapy
- Urothelial Carcinomas
Background:
- Bacillus Calmette-Guérin (BCG) and interferon alpha-2b (IFN alpha 2b) are established treatments for bladder cancer.
- Investigating novel therapeutic combinations is crucial for improving treatment outcomes.
Purpose of the Study:
- To evaluate the safety and efficacy of combining low-dose BCG with IFN alpha 2b for superficial bladder cancer.
- To determine the tolerability and preliminary response rates of this combination therapy.
Main Methods:
- A pilot study involving 12 patients with superficial bladder cancer.
- Patients received weekly low-dose BCG (60 mg) combined with varying doses of IFN alpha 2b (10-100 x 10^6 IU) for 6 weeks.
- Safety and efficacy were assessed over a 12-month follow-up period.
Main Results:
- The combination therapy was well-tolerated, with mild to moderate adverse effects that resolved post-treatment.
- No tumor progression was observed in most patients at 12 months.
- Two patients experienced solitary recurrences, and one had recurrent carcinoma in situ.
Conclusions:
- Combination therapy with low-dose BCG and IFN alpha 2b appears safe and well-tolerated for superficial bladder cancer.
- Early results suggest a high response rate, warranting further investigation in larger clinical trials.
- Phase II and III studies are necessary to definitively establish the efficacy of this treatment regimen.
Objectives:
Bacillus Calmette-Guérin (BCG) and interferon alpha-2b (IFN alpha 2b) have been used individually for the treatment of bladder cancer. We used a low dose of BCG combined with IFN alpha 2b to determine the safety and to assess the efficacy of this combination therapy.
Methods:
A study of 12 patients with superficial bladder cancer evaluated the safety and efficacy of a combination of low-dose BCG and IFN alpha 2b, given weekly for 6 weeks. Three patients were assigned to each of four groups in which 60 mg of BCG was combined with 10, 30, 60, or 100 x 10(6) IU of IFN alpha 2b.
Results:
The combination BCG/IFN alpha 2b therapy was well tolerated, with adverse effects being mild to moderate and resolved at the end of treatment. At 12 months post-treatment there has been no tumor progression. Two patients with previous multifocal transitional cell carcinoma have had solitary recurrences. One patient has had recurrent carcinoma in situ.
Conclusions:
This preliminary study found combination BCG/IFN alpha 2b induction therapy to be safe and well tolerated. These early results show a high response rate, but efficacy can only be determined with Phase II and III studies.